Thomas Harding - Dec 1, 2021 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Senior Vice President and Chief Scientific Officer
Signature
/s/ Thomas Harding
Stock symbol
CLVS
Transactions as of
Dec 1, 2021
Transactions value $
-$444
Form type
4
Date filed
12/3/2021, 03:15 PM
Previous filing
Nov 3, 2021
Next filing
Jan 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +281 +5.35% 5.54K Dec 1, 2021 Direct F1
transaction CLVS Common Stock Sale -$423 -141 -2.55% $3.00* 5.4K Dec 2, 2021 Direct F2
transaction CLVS Common Stock Options Exercise +18 +1.18% 1.55K Dec 1, 2021 By wife F1
transaction CLVS Common Stock Sale -$21 -7 -0.45% $3.00* 1.54K Dec 2, 2021 By wife F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -281 -49.91% $0.00 282 Dec 1, 2021 Common Stock 281 Direct F1, F3
transaction CLVS Restricted Stock Units Options Exercise $0 -18 -48.65% $0.00 19 Dec 1, 2021 Common Stock 18 By wife F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 On March 1, 2018, the reporting person was granted 4,500 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F4 On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer